Minutes - Medication WG 2022-02-15

Attendees

• An Crepel, Digile
• Annemieke Vergauwe
• Bart Decuypere
• Jan Lenie
• Jean-Michel Polfliet
• Jens Penny
• José Costa Teixeira
• Karlien Erauw
• Kris Deceunynck
• Pablo Christiaens
• Thomas Van Langendonck
• Tom Henkens

Excused/Not present

• Anne Nerenhausen
• Bruno Casneuf
• Dieter Sauvillers
• Elhassan Baazizi
• Hanne Vuegen
• Jean-Louis Maggetto
• Jeroen De Wilde
• Katrien Thorré
• Lars Vanreppelen
• Marc Buckens
• Nick Hermans
• Nils Devos
• Richard Francken
• Thomas Van Langendonck
• Tom De Backer
• Walter Bollaert
• Will van Norel

Agenda

• presentation and discussion on drug databases

Minutes

• An from Digile has worked on the SAM database and has plenty of drug data expertise

• BCFI, the green booklet used by pharmacists & doctors

• BCFI was structured in a Repertorium drug tables

• SAM is a consortium: APB, RIZIV, FOD VG, FAGG to put all drugs in one database

• VMP, VMP-groups are concepts that were implemented through guidance from BCFI

• the public SAM viewer was developed by Digile, visualisation in an intuitive manner that has the full SAMv2 content (2 updates a day - not realtime), search is intuitive by brand, substance, code (CTI-extended, CNK), has the business history

• feedback option is available for the pharma and industry as there are still some data quality issues & inconsistencies with SAM

• follow-up on raised issues is still difficult

• CSV experts are available f.e. for overview of VOS-groups to improve easier access to these data that was not open to the public before

• ISO IDMP gap analysis on SAM V2 has been done

• ISO IDMP does not present a fixed vocabulary
• objective is to map SAMv2 to ISO IDMP database, works quite well although there are no identifiers in the 2 systems
• attributes can be useful for the mapping

• How can we query with FHIR on SAMv2 ? There is a restful API but not on FHIR

• f.e. if doctor wants to query on substance
• what are the logical models behind: see https://www.samportal.be/nl/sam/documentation PIM logical model

• what is a VMP group: it is a clinical concept for medicinal products having the same substance, strength, pharmaceutical form and route of administration - seen from the point of view of a clinician (doctor, pharmacist)
• VMP is a more regulatory concept
• our WG goal: how to represent medication in a medication scheme - which recommendation to represent the medication ? The current MS is focused on brand name ; VOS-group of substance seems better from a clinical point of view as it includes the route of administration

• RIZIV wants a different view so both levels will have to be there (packages)

• The VIDIS project would like to have first artefacts of our WG

• medication treatment line are being worked on - we need some use cases/examples to make progress - will be ready for next meeting

• We have started working on a document listing different concepts that will be used in the medication scheme. This document will be presented in next meeting

Action items for next meeting

• José to work on use cases and add medication view line in view and how it all works at operational level

Agenda items for next meeting

• medication treatment line examples
• discuss document

Next meeting March 1 at 11AM